{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:41Z","timestamp":1793316581944,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["PS3416"],"award-info":[{"award-number":["PS3416"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023178","name":"Cancer Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009253","name":"EASL International Liver Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jhepr.2021.100347","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T12:30:30Z","timestamp":1628166630000},"page":"100347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":186,"title":["ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-2740","authenticated-orcid":false,"given":"Coskun O.","family":"Demirtas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jhepr.2021.100347_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Canc"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/hep.27222","article-title":"Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?","volume":"60","author":"El-Serag","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhepr.2021.100347_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13651820410024058","article-title":"Staging systems in hepatocellular carcinoma","volume":"7","author":"Pons","year":"2005","journal-title":"HPB (Oxford)"},{"issue":"8","key":"10.1016\/j.jhepr.2021.100347_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/he.2000.5628","article-title":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators","volume":"31","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s005350300038","article-title":"Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)","volume":"38","author":"Kudo","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.clon.2016.11.012","article-title":"Sorafenib for the treatment of advanced hepatocellular cancer - a UK audit","volume":"29","author":"King","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jhepr.2021.100347_bib12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/liv.13170","article-title":"A\u00a0multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma","volume":"36","author":"Edeline","year":"2016","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-2008-1040325","article-title":"Assessment of prognosis of cirrhosis","volume":"28","author":"Durand","year":"2008","journal-title":"Semin Liver Dis"},{"issue":"11-12","key":"10.1016\/j.jhepr.2021.100347_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2005.02691.x","article-title":"Systematic review: the model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?","volume":"22","author":"Cholongitas","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhepr.2021.100347_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"10127","key":"10.1016\/j.jhepr.2021.100347_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jhepr.2021.100347_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/bjs.10095","article-title":"Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma","volume":"103","author":"Wang","year":"2016","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.jhepr.2021.100347_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hepr.12796","article-title":"Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: validation in a Chinese cohort","volume":"47","author":"Li","year":"2017","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib20","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1038\/s41598-018-22923-4","article-title":"Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection","volume":"8","author":"Ho","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jhepr.2021.100347_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.21037\/atm.2020.02.85","article-title":"Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jhepr.2021.100347_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cca.2016.08.005","article-title":"Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma","volume":"462","author":"Ma","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"18","key":"10.1016\/j.jhepr.2021.100347_bib23","first-page":"3862","article-title":"Preoperative albumin-bilirubin score for postoperative solitary hepatocellular carcinoma within the Milan criteria and Child-Pugh A cirrhosis","volume":"8","author":"Dong","year":"2017","journal-title":"J\u00a0Canc"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.14701\/ahbps.2018.22.4.335","article-title":"Effectiveness of the albumin-bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma","volume":"22","author":"Lee","year":"2018","journal-title":"Ann Hepatobil Pancreat Surg"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ejso.2018.10.541","article-title":"Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma","volume":"45","author":"Ho","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2021.100347_bib26","first-page":"1693","article-title":"Novel prognostic nomograms for predicting early and late recurrence of hepatocellular carcinoma after curative hepatectomy","volume":"12","author":"Xu","year":"2020","journal-title":"Canc Manag Res"},{"key":"10.1016\/j.jhepr.2021.100347_bib27","first-page":"3503","article-title":"Development and validation of pre- and post-operative models to predict recurrence after resection of solitary hepatocellular carcinoma: a multi-institutional study","volume":"12","author":"Wu","year":"2020","journal-title":"Canc Manag Res"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00268-019-05197-3","article-title":"The ALBI grade is a good predictive model for very late recurrence in patients with hepatocellular carcinoma undergoing primary resection","volume":"44","author":"Lin","year":"2020","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib29","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1038\/s41598-020-64354-0","article-title":"Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery","volume":"10","author":"Cho","year":"2020","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.jhepr.2021.100347_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21037\/atm.2019.06.01","article-title":"Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy","volume":"7","author":"Ye","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jhepr.2021.100347_bib31","first-page":"101534","article-title":"A\u00a0novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma","author":"Shi","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhepr.2021.100347_bib32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.hbpd.2018.07.011","article-title":"Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection","volume":"17","author":"Amisaki","year":"2018","journal-title":"Hepatobil Pancreat Dis Int"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/liv.13514","article-title":"Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients","volume":"38","author":"Zou","year":"2018","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jamcollsurg.2019.12.007","article-title":"Albumin-bilirubin score vs model for end-stage liver disease in predicting post-hepatectomy outcomes","volume":"230","author":"Fagenson","year":"2020","journal-title":"J\u00a0Am Coll Surg"},{"issue":"7","key":"10.1016\/j.jhepr.2021.100347_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/jso.25721","article-title":"The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma","volume":"120","author":"Kornberg","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib36","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.transproceed.2020.01.020","article-title":"Impact of albumin-bilirubin score on short- and long-term survival after living-donor liver transplantation: a retrospective study","volume":"52","author":"Tai","year":"2020","journal-title":"Transpl Proc"},{"issue":"11","key":"10.1016\/j.jhepr.2021.100347_bib37","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s10620-017-4775-8","article-title":"Liver function assessment using albumin-bilirubin grade for patients with very early-stage hepatocellular carcinoma treated with radiofrequency ablation","volume":"62","author":"Oh","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.20892\/j.issn.2095-3941.2018.0486","article-title":"Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation","volume":"16","author":"An","year":"2019","journal-title":"Canc Biol Med"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/JCMA.0000000000000001","article-title":"Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy","volume":"82","author":"Chen","year":"2019","journal-title":"J\u00a0Chin Med Assoc"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1148\/radiol.2017162382","article-title":"Hepatocellular carcinoma: nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation","volume":"285","author":"Kao","year":"2017","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.jhepr.2021.100347_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrclinonc.2014.122","article-title":"Treatment of intermediate-stage hepatocellular carcinoma","volume":"11","author":"Forner","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhepr.2021.100347_bib44","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/apt.14066","article-title":"Review article: delivering precision oncology in intermediate-stage liver cancer","volume":"45","author":"Pinato","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib45","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.jhepr.2021.100347_bib46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1159\/000439290","article-title":"Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's subclassification (Kinki criteria)","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig Dis"},{"issue":"7","key":"10.1016\/j.jhepr.2021.100347_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180408","article-title":"Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"12","author":"Ho","year":"2017","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/bjc.2016.423","article-title":"Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion","volume":"116","author":"Waked","year":"2017","journal-title":"Br J Canc"},{"issue":"9","key":"10.1016\/j.jhepr.2021.100347_bib49","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/liv.14194","article-title":"A\u00a0new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma","volume":"39","author":"Lee","year":"2019","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvir.2018.08.026","article-title":"Nomogram and artificial neural network for prognostic performance on the albumin-bilirubin grade for hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"30","author":"Zhong","year":"2019","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib51","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00330-019-06438-8","article-title":"A\u00a0nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation","volume":"30","author":"Ni","year":"2020","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12885-020-06975-2","article-title":"A\u00a0differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function","volume":"20","author":"Nam","year":"2020","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.jhepr.2021.100347_bib53","doi-asserted-by":"crossref","first-page":"538","DOI":"10.21037\/atm.2020.02.124","article-title":"Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib54","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s10620-020-06384-2","article-title":"Albumin-bilirubin (ALBI) grade-based nomogram for patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"66","author":"Ho","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib55","doi-asserted-by":"crossref","first-page":"840","DOI":"10.21037\/jgo.2018.05.14","article-title":"Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma","volume":"9","author":"Mohammadi","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"9","key":"10.1016\/j.jhepr.2021.100347_bib56","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/COC.0000000000000384","article-title":"Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization","volume":"41","author":"Gui","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2021.100347_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060879","article-title":"Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization","volume":"11","author":"Antkowiak","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.jhepr.2021.100347_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2018.06.016","article-title":"Albumin-bilirubin score: an accurate predictor of hepatic decompensation in high-risk patients undergoing transarterial chemoembolization for hepatocellular carcinoma","volume":"29","author":"Mohammed","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijrobp.2017.04.036","article-title":"Comparison between Child-Turcotte-pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiation therapy","volume":"99","author":"Lo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib60","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ijrobp.2018.04.011","article-title":"Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT)","volume":"101","author":"Murray","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00066-017-1256-0","article-title":"The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy","volume":"194","author":"Gkika","year":"2018","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13014-019-1251-y","article-title":"Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy","volume":"14","author":"Su","year":"2019","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10620-020-06245-y","article-title":"Selective internal radiation therapy for hepatocellular carcinoma across the Barcelona clinic liver cancer stages","volume":"66","author":"Moctezuma-Velazquez","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10126","key":"10.1016\/j.jhepr.2021.100347_bib66","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jhepr.2021.100347_bib67","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib68","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","article-title":"Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study","volume":"19","author":"Miksad","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000480441","article-title":"Treatment stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study","volume":"6","author":"Yen","year":"2017","journal-title":"Liver Cancer"},{"issue":"32","key":"10.1016\/j.jhepr.2021.100347_bib70","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/apt.13904","article-title":"The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development","volume":"45","author":"Pinato","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib73","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/liv.13527","article-title":"Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma","volume":"38","author":"Lee","year":"2018","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib74","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00432-018-2610-z","article-title":"Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study","volume":"144","author":"Abdel-Rahman","year":"2018","journal-title":"J\u00a0Canc Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2021.100347_bib75","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jgh.14564","article-title":"Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic","volume":"34","author":"Tada","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3-4","key":"10.1016\/j.jhepr.2021.100347_bib76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000502714","article-title":"Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience","volume":"6","author":"Rovesti","year":"2019","journal-title":"Gastrointest Tumors"},{"issue":"12","key":"10.1016\/j.jhepr.2021.100347_bib77","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/jgh.13783","article-title":"Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use","volume":"32","author":"Kuo","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2021.100347_bib78","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3390\/cancers11091256","article-title":"Baseline and early predictors of good patient candidates for second-line after sorafenib treatment in unresectable hepatocellular carcinoma","volume":"11","author":"Takada","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2021.100347_bib79","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.524","article-title":"Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC)","volume":"38","author":"Vogel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.jhepr.2021.100347_bib80","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/cancers11070952","article-title":"Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study","volume":"11","author":"Ueshima","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jhepr.2021.100347_bib81","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/cancers12071867","article-title":"Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study","volume":"12","author":"Shimose","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jhepr.2021.100347_bib82","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/nu12041076","article-title":"Controlling nutritional status (CONUT) score is associated with overall\u00a0survival in patients with unresectable hepatocellular carcinoma\u00a0treated\u00a0with lenvatinib: a multicenter cohort study","volume":"12","author":"Shimose","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.jhepr.2021.100347_bib83","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hepr.13460","article-title":"Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study","volume":"50","author":"Hatanaka","year":"2020","journal-title":"Hepatol Res"},{"issue":"10","key":"10.1016\/j.jhepr.2021.100347_bib84","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3390\/cancers12102906","article-title":"Liver function changes in patients with hepatocellular carcinoma\u00a0treated with lenvatinib: predictive factors of progression\u00a0to\u00a0Child-Pugh class B, the formation of ascites and the candidates for the post-progression treatment","volume":"12","author":"Hatanaka","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100347_bib85","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000506293","article-title":"Nutritional index as prognostic indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma","volume":"98","author":"Hiraoka","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2021.100347_bib86","doi-asserted-by":"crossref","first-page":"ix45","DOI":"10.1093\/annonc\/mdz422.005","article-title":"Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib87","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.jhepr.2020.100215","article-title":"Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2","volume":"3","author":"Kudo","year":"2021","journal-title":"JHEP Rep"},{"issue":"10","key":"10.1016\/j.jhepr.2021.100347_bib88","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/liv.14573","article-title":"Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study","volume":"40","author":"Kim","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib89","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"suppl_4","key":"10.1016\/j.jhepr.2021.100347_bib90","article-title":"Checkmate-040: nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status","volume":"37","author":"Kudo","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2021.100347_bib91","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/cancers12010182","article-title":"Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2021.100347_bib92","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3389\/fonc.2020.01043","article-title":"Real-world outcomes of nivolumab in patients with unresectable hepatocellular carcinoma in an endemic area of hepatitis B virus infection","volume":"10","author":"Sung","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2021.100347_bib93","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J\u00a0Immunother Canc"},{"issue":"7","key":"10.1016\/j.jhepr.2021.100347_bib94","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/cancers12071862","article-title":"Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade","volume":"12","author":"Pinato","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jhepr.2021.100347_bib95","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/liv.14533","article-title":"Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma","volume":"40","author":"Rimassa","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100347_bib96","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.029","article-title":"LBA38PR CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2021.100347_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.483","article-title":"CheckMate 459: health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"38","author":"Edeline","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:05:53Z","timestamp":1778904353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2589555921001233"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100347","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100347"}}